Alentis Therapeutics
Alentis is developing treatments for fibrotic disease and associated cancer by exploiting Claudin-1 (CLDN1) and its associated pathways.
Enyo Pharma
Biomimetics for Liver Disorders
Targeting the biochemical pathways underlying behind virus-host interactions, Enyo Pharma is developing a novel class of non-bile acid FXR agonists for the treatment of Hepatitis B and nonalcoholic steatohepatitis (fatty liver disease).
Enyo's lead candidate, EYP001, has shown promising results in patients in both indications and has demonstrated a differentiated safety profile compared to other FXR agonists. This compound is currently in Phase 2 clinical trials.
InCarda Therapeutics
Transforming Cardiovascular Treatment with Pulmonary Delivery
Paroxysmal atrial fibrillation affects over 34 million people worldwide – InCarda is developing inhaled therapeutics to address this patient population. The advantage of inhalation is that it delivers medicine in the “first pass” to cardiac tissue, presenting a small, but effective dose of drug directly to affected regions of the heart. This permits rapid-onset, lower off-target tissue exposure of the drug and can be patient self-administered anywhere PAF episodes may occur. InCarda’s therapeutic is in Phase 2 clinical trials.
NewAmsterdam Pharma
Transformative Therapies for Cardio-Metabolic Diseases
NewAmsterdam Pharma is a clinical-stage company focused on the research and development of transformative therapies for cardio-metabolic diseases. Its mission is to improve patient care in populations where traditional therapies have been unsuccessful or are not tolerated.